Elicio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies for the treatment of cancer. Its lead product candidate, ELI-002, is a multivalent lymph node-targeted amphiphile (AMP) peptide vaccine that is in Phase II clinical trials for seven Kirsten rat sarcoma viral oncogene homolog driver mutations. The company also develops ELI-007, a multivalent lymph node-targeted AMP peptide treatment for mutant b-raf murine sarcoma viral oncogene homolog B1-(BRAF) driven cancers, and ELI-008, a multivalent lymph node-targeted AMP peptide vaccine in preclinical studies for the treatment of mutated tumor protein p53-expressing cancers. Elicio Therapeutics, Inc. is headquartered in Boston, Massachusetts. Show more

451 D Street, Boston, MA, 02210, United States

Biotechnology
Healthcare

Market Cap

73.48M

52 Wk Range

$2.66 - $16.00

Previous Close

$3.85

Open

$3.95

Volume

3,152,444

Day Range

$3.76 - $4.49

Enterprise Value

72.87M

Cash

14.95M

Avg Qtr Burn

-11.65M

Insider Ownership

29.76%

Institutional Own.

17.01%

Qtr Updated

03/31/26